{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T15:46:40Z","timestamp":1763480800695},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,22]]},"DOI":"10.7759\/cureus.69904","type":"journal-article","created":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T11:53:11Z","timestamp":1727005991000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the Efficacy and Safety of Low Molecular Weight Heparins and Fondaparinux in Patients With COVID-19: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Laith G","family":"Shareef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa M","family":"Noori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aumnia G","family":"Shareef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"COVID-19 clinical characteristics and outcomes in 60 hospitalized Iraqi patients \u2014\u00a0case series","volume":"24","author":"Bonyan FA","year":"2020","unstructured":"Bonyan FA, Shareef LG, Al-waily A, et al.. COVID-19 clinical characteristics and outcomes in 60 hospitalized Iraqi patients \u2014\u00a0case series. Med Sci. 2020, 24:2251-2258.","journal-title":"Med Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00655-6","article-title":"Major coagulation disorders and parameters in COVID-19 patients","volume":"27","author":"Teimury A","year":"2022","unstructured":"Teimury A, Khameneh MT, Khaledi EM. Major coagulation disorders and parameters in COVID-19 patients. Eur J Med Res. 2022, 27:25. 10.1186\/s40001-022-00655-6","journal-title":"Eur J Med Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S280962","article-title":"D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review","volume":"16","author":"Eljilany I","year":"2020","unstructured":"Eljilany I, Elzouki AN. D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review. Vasc Health Risk Manag. 2020, 16:455-462. 10.2147\/VHRM.S280962","journal-title":"Vasc Health Risk Manag"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13547","article-title":"COVID-19-related laboratory coagulation findings","volume":"43","author":"Devreese KM","year":"2021","unstructured":"Devreese KM. COVID-19-related laboratory coagulation findings. Int J Lab Hematol. 2021, 43:36-42. 10.1111\/ijlh.13547","journal-title":"Int J Lab Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-022-02643-3","article-title":"Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum","volume":"54","author":"Barnes GD","year":"2022","unstructured":"Barnes GD, Burnett A, Allen A, et al.. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2022, 54:197-210. 10.1007\/s11239-022-02643-3","journal-title":"J Thromb Thrombolysis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007561","article-title":"American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients","volume":"6","author":"Cuker A","year":"2022","unstructured":"Cuker A, Tseng EK, Nieuwlaat R, et al.. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv. 2022, 6:4915-4923. 10.1182\/bloodadvances.2022007561","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.110545.2","article-title":"COVID-19 vaccination hesitancy among Iraqi general population between beliefs and barriers: an observational study","volume":"11","author":"Shareef LG","year":"2022","unstructured":"Shareef LG, Fawzi Al-Hussainy A, Majeed Hameed S. COVID-19 vaccination hesitancy among Iraqi general population between beliefs and barriers: an observational study. F1000Res. 2022, 11:334. 10.12688\/f1000research.110545.2","journal-title":"F1000Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab849.169","article-title":"Efficacy and safety of fondaparinux versus unfractionated heparin in patients hospitalised with severe COVID-19 pneumonia and coagulopathy: a randomised, open-label clinical trial","volume":"43","author":"Adrian LH","year":"2022","unstructured":"Adrian LH, Hutomo SA, Negari AD. Efficacy and safety of fondaparinux versus unfractionated heparin in patients hospitalised with severe COVID-19 pneumonia and coagulopathy: a randomised, open-label clinical trial. Eur Heart J. 2022, 43:ehab849.169. 10.1093\/eurheartj\/ehab849.169","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15809","article-title":"Good practice statements for antithrombotic therapy in the management of COVID-19: guidance from the SSC of the ISTH","volume":"20","author":"Spyropoulos AC","year":"2022","unstructured":"Spyropoulos AC, Connors JM, Douketis JD, et al.. Good practice statements for antithrombotic therapy in the management of COVID-19: guidance from the SSC of the ISTH. J Thromb Haemost. 2022, 20:2226-2236. 10.1111\/jth.15809","journal-title":"J Thromb Haemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S285214","article-title":"Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients: the FONDENOXAVID study","volume":"12","author":"Cardillo G","year":"2021","unstructured":"Cardillo G, Viggiano GV, Russo V, et al.. Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients: the FONDENOXAVID study. J Blood Med. 2021, 12:69-75. 10.2147\/JBM.S285214","journal-title":"J Blood Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.569567","article-title":"Thromboprofilaxys with fondaparinux vs. enoxaparin in hospitalized COVID-19 patients: a multicenter Italian observational study","volume":"7","author":"Russo V","year":"2020","unstructured":"Russo V, Cardillo G, Viggiano GV, et al.. Thromboprofilaxys with fondaparinux vs. enoxaparin in hospitalized COVID-19 patients: a multicenter Italian observational study. Front Med (Lausanne). 2020, 7:569567. 10.3389\/fmed.2020.569567","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.11788","article-title":"Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19","volume":"4","author":"Vaughn VM","year":"2021","unstructured":"Vaughn VM, Yost M, Abshire C, et al.. Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19. JAMA Netw Open. 2021, 4:e2111788. 10.1001\/jamanetworkopen.2021.11788","journal-title":"JAMA Netw Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim SY","year":"2020","unstructured":"Kim SY, Jin W, Sood A, et al.. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res. 2020, 181:104873. 10.1016\/j.antiviral.2020.104873","journal-title":"Antiviral Res"},{"key":"ref15","article-title":"Trends in covid-19 therapeutic modalities: a narrative literature","volume":"7","author":"Shareef LG","year":"2020","unstructured":"Shareef LG, Abdulwahab SM. Trends in covid-19 therapeutic modalities: a narrative literature. Eur J Pharm Med Res. 2020, 7:757-767.","journal-title":"Eur J Pharm Med Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2180","article-title":"Anticoagulation outcomes in hospitalized Covid-19 patients: a systematic review and meta-analysis of case-control and cohort studies","volume":"31","author":"Kamel AM","year":"2021","unstructured":"Kamel AM, Sobhy M, Magdy N, Sabry N, Farid S. Anticoagulation outcomes in hospitalized Covid-19 patients: a systematic review and meta-analysis of case-control and cohort studies. Rev Med Virol. 2021, 31:e2180. 10.1002\/rmv.2180","journal-title":"Rev Med Virol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620960797","article-title":"The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review","volume":"26","author":"Wijaya I","year":"2020","unstructured":"Wijaya I, Andhika R, Huang I. The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review. Clin Appl Thromb Hemost. 2020, 26:10.1177\/1076029620960797","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1726034","article-title":"Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis","volume":"47","author":"Parisi R","year":"2021","unstructured":"Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost. 2021, 47:372-391. 10.1055\/s-0041-1726034","journal-title":"Semin Thromb Hemost"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/293594-comparison-of-the-efficacy-and-safety-of-low-molecular-weight-heparins-and-fondaparinux-in-patients-with-covid-19-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T11:53:13Z","timestamp":1727005993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/293594-comparison-of-the-efficacy-and-safety-of-low-molecular-weight-heparins-and-fondaparinux-in-patients-with-covid-19-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.69904","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,22]]}}}